Hologic, Inc.
HOLX
Helyezés a részvények között
#1330
Hologic, Inc. is a medical technology company focused on designing, producing,... Hologic, Inc. is a medical technology company focused on designing, producing, and marketing a diverse range of diagnostic tests, medical imaging systems, and surgical solutions. Its core mission is to enhance women's health through proactive detection and effective treatment, serving patients in the United States, across Europe, the Asia-Pacific region, and various other international markets. The company operates through four distinct business units: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. Within its Diagnostics segment, Hologic provides Aptima molecular diagnostic assays for identifying infectious microorganisms, alongside Aptima viral load tests for conditions like HIV, Hepatitis C, and Hepatitis B. It also offers Aptima and Panther Fusion SARS-CoV-2 assays for detecting the virus, the ThinPrep System for cytology applications, and the Rapid Fetal Fibronectin Test to help clinicians assess the likelihood of premature birth. Furthermore, the company supplies various diagnostic tests for Group B Streptococcus. The Breast Health division delivers advanced imaging and analytical solutions, including 2D and 3D digital mammography systems with accompanying reading workstations. This segment also features minimally invasive breast biopsy guidance systems and devices, products for marking and localizing breast biopsy sites, specimen radiology tools, ultrasound solutions, connectivity options, and products supporting breast-conserving surgical procedures. For GYN Surgical needs, Hologic offers the NovaSure Endometrial Ablation System, designed to manage abnormal uterine bleeding, and the MyoSure Hysteroscopic Tissue Removal System for the excision of uterine fibroids, polyps, and other pathologies. Additionally, the Fluent Fluid Management System facilitates liquid distention during diagnostic and operative hysteroscopic interventions. The Skeletal Health segment includes the Horizon DXA, a dual-energy X-ray system, and the Fluoroscan Insight FD mini C-arm, which is utilized for minimally invasive orthopedic surgical procedures. Hologic distributes its comprehensive product portfolio through a combination of its dedicated direct sales and service teams, as well as via independent distributors and sales representatives. Established in 1985, Hologic, Inc. maintains its corporate headquarters in Marlborough, Massachusetts.
Részvényárfolyam
$76.01
Utolsó szinkronizálás: 2026-04-07
Piaci kapitalizáció
$16.97B
Változás (1 nap)
0.00%
Változás (1 év)
2.74%
Ország
US
Kereskedés Hologic, Inc. (HOLX)
Kategória
Healthcare
Hologic, Inc. (HOLX) nyeresége
Nyereség ekkor: Dec 2025 TTM: $663.60M
Hologic, Inc. legfrissebb pénzügyi jelentései szerint a vállalat jelenlegi nyeresége $663.60M. 2024 évben a vállalat $865.10M nyereséget ért el, növekedés a 2023 év nyereségéhez, amely $676.10M volt. Az ezen az oldalon megjelenített nyereség a kamatok és adók előtti eredmény, azaz EBIT.
Hologic, Inc. nyereségtörténete 2000 és 2026 között
Nyereség az év végén
| Év | Nyereség | Változtassa meg |
|---|---|---|
| 2026 (TTM) | $663.60M | -2.58% |
| 2025 | $681.20M | -21.26% |
| 2024 | $865.10M | 27.95% |
| 2023 | $676.10M | -57.43% |
| 2022 | $1.59B | -32.73% |
| 2021 | $2.36B | 135.66% |
| 2020 | $1.00B | -1,151.31% |
| 2019 | $-95.30M | -77.23% |
| 2018 | $-418.60M | -134.02% |
| 2017 | $1.23B | 196.29% |
| 2016 | $415.30M | 134.37% |
| 2015 | $177.20M | 268.40% |
| 2014 | $48.10M | -104.03% |
| 2013 | $-1.19B | 1,834.71% |
| 2012 | $-61.66M | -127.12% |
| 2011 | $227.39M | -513.50% |
| 2010 | $-54.99M | -97.37% |
| 2009 | $-2.09B | 648.25% |
| 2008 | $-279.14M | -287.99% |
| 2007 | $148.49M | 178.99% |
| 2006 | $53.22M | 53.40% |
| 2005 | $34.70M | 168.39% |
| 2004 | $12.93M | 295.93% |
| 2003 | $3.27M | -1,406.00% |
| 2002 | $-250.00K | -98.79% |
| 2001 | $-20.68M | -28.73% |
| 2000 | $-29.02M | 0.00% |
Hasonló cégek vagy versenytársak nyeresége
| Vállalat | Nyereség | Nyereségkülönbség | Ország |
|---|---|---|---|
| $3.81B | 473.51% |
US
|
|
| $4.11B | 519.17% |
FR
|
|
| - | - |
JP
|
|
| $1.59B | 139.60% |
US
|
|
| - | - |
CH
|
